Lung Adenocarcinoma

Response to Afatinib was assessed by measuring viability of Ba/F3 cells expressing the EGFR::RAD51 variant 72 hours after treatment with Afatinib (10-1000 nmol/L). Viability was measured using the Cel… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

The paper reports three patients (P1, P2 and P4) with Stage IV lung adenocarcinoma with metastasis, harboring the EGFR::RAD51 fusion detected by hybrid capture NGS (FoundationOne). Breakpoints were in… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

A 48-year-old Chinese man with right lung tumor and multiple brain metastases of a lung adenocarcinoma (T1N2M1, stage IV). NGS analysis indicated an EGFR-RAD51 fusion rather than the most common kind… (full text at CIViC)

PMID 29290255 · Zhu et al., 2018 · Open in CIViC

Response to Erlotinib was assessed by measuring viability of Ba/F3 cells expressing the EGFR::RAD51 variant 72 hours after treatment with Erlotinib (10-1000 nmol/L). Viabilty was measured using the Ce… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

This is a case report of 29-year-old diagnosed with metastatic adenocarcinoma of the left lung. The patient was treated with chemotherapy (cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 every 3 weeks) an… (full text at CIViC)

PMID 35399574 · Di Federico et al., 2022 · Open in CIViC

A 26 year old non-smoker was diagnosed with lung adenocarcinoma and underwent thoracoscopic resection and treatment with cisplatin and pemetrexed. Panel NGS sequencing of the surgical sample detected … (full text at CIViC)

PMID 31064887 · Guan et al., 2019 · Open in CIViC

Case report of a 30-year-old male with lung adenocarcinoma and metastasis to several organs, including several lesions in the brain. NGS assay (Foundation One CDX panel) detected the EGRF::RAD51 fusio… (full text at CIViC)

PMID 35245845 · Copia Sperandio et al., 2022 · Open in CIViC

This is a case report of a 45-year-old male never smoker that was diagnosed with metastatic lung adenocarcinoma. The patient responded poorly to the initial chemoimmunotherapy (carboplatin, pemetrexed… (full text at CIViC)

PMID 38525318 · Lai et al., 2024 · Open in CIViC

A Japanese Phase III clinical study assessed the noninferiority of gefitinib as compared to erlotinib in 561 advanced stage (IIIB and IV) postoperative lung adenocarcinoma patients. All patients had p… (full text at CIViC)

PMID 27022112 · Urata et al., 2016 · Open in CIViC

Efficacy of erlotinib treatment was evaluated by meta-analysis of results from seven trials and literature review. Two patients with p.S270P, and one patient with p.S720F were observed to have poor su… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR S768_D770insSVD mutation was associated with resistance to erlotinib treatment. The patient su… (full text at CIViC)

PMID 27032107 · De Grève et al., 2016 · Open in CIViC

A 48-year-old man with stage IVB lung adenocarcinoma harboring an EGFR S768_D770dup exon 20 insertion and high PD-L1 expression (TPS 50%) received third-line paclitaxel plus tislelizumab after progres… (full text at CIViC)

PMID 42558558 · Zhao et al., 2026 · Open in CIViC

A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor sam… (full text at CIViC)

PMID 25521405 · Hellmann et al., 2014 · Open in CIViC

In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously trea… (full text at CIViC)

PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC

In a phase 2 trial, 129 patients with lung adenocarcinoma with EGFR mutations including mutations other than exon 19 deletions or exon 21 L858R substitutions who had no more than one previous chemothe… (full text at CIViC)

PMID 22452895 · Yang et al., 2012 · Open in CIViC

A case report of a 56 year old male with metastatic lung adenocarcinoma to the leptomeninges, in whom two rare EGFR::SEPT14 fusions were identified. On second recurrence, NGS was performed on the CSF,… (full text at CIViC)

PMID 34486539 · Zheng et al., 2022 · Open in CIViC

Case report of a 62-year-old woman with lung adenocarcinoma. She underwent treatment with liposome-paclitaxel and carboplatin. They detected EGFR-SEPT14 fusion (N-terminal amino acids of EGFR and C-te… (full text at CIViC)

PMID 31345345 · Zhu et al., 2019 · Open in CIViC

This article identified in-frame EGFR-SHC1 fusions in a 61-year-old male smoker with stage IIIA NSCLC, retaining functional kinase domains. RNA-based NGS fusion assays was used for detecting actionabl… (full text at CIViC)

PMID 31382039 · Pan et al., 2019 · Open in CIViC

In this study, the authors employed next-generation sequencing (NGS) to compare the genetic profiles of lung adenocarcinoma (LUAD) patients with and without adrenal metastases. An EGFR-SUMF2 fusion wa… (full text at CIViC)

PMID 39673828 · Pan et al., 2025 · Open in CIViC

T725M and L861R are rare cancer-associated mutations and increase EGFR activity in the absence of the activating EGF ligand in cell-based assays

PMID 24743239 · U et al., 2014 · Open in CIViC

In this study, the authors investigated the role of the EGFR T790M mutation using inducible mouse lung tumor models expressing T790M alone or in combination with the activating L858R mutation. They de… (full text at CIViC)

PMID 17726540 · Regales et al., 2007 · Open in CIViC

A 53-year-old Chinese man and lifelong non-smoker presented with chest tightness and pain. CT scans revealed multiple small lung nodules in the right lower lobe were seen with CT scan. Biopsy confirme… (full text at CIViC)

PMID 38074875 · Xiang et al., 2023 · Open in CIViC

A 53-year-old Chinese man, a lifelong non-smoker, presented with chest tightness and pain. CT imaging revealed multiple small nodules in the right lower lobe of the lung. A biopsy confirmed stage IV l… (full text at CIViC)

PMID 38074875 · Xiang et al., 2023 · Open in CIViC

Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After fur… (full text at CIViC)

PMID 26181354 · Yu et al., 2015 · Open in CIViC

Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After fur… (full text at CIViC)

PMID 26181354 · Yu et al., 2015 · Open in CIViC

A 53-year old man (non-smoker) presented with chest tightness and pain and was revealed to have stage IV lung adenocarcinoma with EGFR exon 19 deletion. The patient started first-line Erlotinib at 150… (full text at CIViC)

PMID 38074875 · Xiang et al., 2023 · Open in CIViC

A patient was initially diagnosed with stage IIIA lung adenocarcinoma with EGFR L858R and was treated with lobectomy and adjuvant pemetrexed and cisplatin. 20 months later the patient had recurrent di… (full text at CIViC)

PMID 35004270 · Wang et al., 2021 · Open in CIViC

In a lung adenocarcinoma patient with EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitor) and EGFR T854A co-mutation, EGFR T854A was reported to be refractory to erlotinib trea… (full text at CIViC)

PMID 19010870 · Bean et al., 2008 · Open in CIViC

One case with presumably EGFR::USP42 fusion was mentioned in OrigiMed database of Chinese patients with lung adenocarcinoma. EGFR breakpoint in intron 27.

PMID 31064887 · Guan et al., 2019 · Open in CIViC

In an advanced lung adenocarcinoma patient with EGFR V769A mutation, EGFR V769A was reported to be sensitive to erlotinib treatment. The patient was treated with 1st-line standard chemotherapy, radiot… (full text at CIViC)

PMID 24908064 · Xing et al., 2014 · Open in CIViC

In this meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, 1 patient with V769_770insASV had overall and progression-free survival of 642 days. From this and literature review it… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

A 72 year old F never smoker with bronchioloalveolar carcinoma who had previously undergone surgery was tested for mutation in EGFR exons 18 to 21 and had Exon 20 in frame insertion. She was given fir… (full text at CIViC)

PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC

In a lung adenocarcinoma patient harboring EGFR V774_C775insHV mutation, EGFR V774_C775insHV was associated with lack of response to treatment with erlotinib monotherapy.

PMID 23371856 · Arcila et al., 2013 · Open in CIViC

Using NGS, genomic profiling from tumor/plasma biopsies from 17,442 Chinese lung cancer patients was performed. EGFR::VSTM2A reported in 2/1053 recurrent kinase fusions in lung cancer (NSCLC, adenocar… (full text at CIViC)

PMID 34508169 · Li et al., 2021 · Open in CIViC

In a Japanese Phase III trial, noninferiority of gefitinib in comparison to erlotinib was assessed in lung adenocarcinoma patients with postoperative or recurrent stage IIIb/IV lung adenocarcinoma tre… (full text at CIViC)

PMID 27022112 · Urata et al., 2016 · Open in CIViC

This is a case report of a patient with lung adenocarcinoma harboring EGFR::RAD51 fusion, however describes other EGFR fusions in lung adenocarcinoma. The authors examined data from the database of Or… (full text at CIViC)

PMID 31064887 · Guan et al., 2019 · Open in CIViC

A 28 year-old patient with non-small cell lung cancer that failed conventional therapy was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotini… (full text at CIViC)

PMID 20979473 · Choi et al., 2010 · Open in CIViC

A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was ther… (full text at CIViC)

PMID 23181703 · Tanaka et al., 2012 · Open in CIViC

EML4-ALK fusion positive lung adenocarcinoma cell lines with high expression of P-gp (ABCB1 gene) (H3122 and the newly established JFCR013-2) were found to be resistant to crizotinib and ceritinib. P-… (full text at CIViC)

PMID 26870817 · Katayama et al., 2016 · Open in CIViC

EML4-ALK fusion positive lung adenocarcinoma cell lines (H3122 and the newly established JFCR013-2) with high expression of P-gp (ABCB1 gene) were found to be resistant to crizotinib and ceritinib. P… (full text at CIViC)

PMID 26870817 · Katayama et al., 2016 · Open in CIViC

A 28 year-old patient with T4N3M1 stage lung adenocarcinoma harboring an EML4-ALK variant 1 fusion was treated with crizotinib after failing conventional therapy. The patient achieved a partial respon… (full text at CIViC)

PMID 20979473 · Choi et al., 2010 · Open in CIViC

In a lung adenocarcinoma cancer patient with an EML4-ALK gene rearrangement (a known sensitizing alteration to crizotinib) and an ALK C1156Y co-mutation, ALK C1156Y was reported to be refractory to cr… (full text at CIViC)

PMID 27045755 · Saber et al., 2016 · Open in CIViC

In a lung adenocarcinoma cancer patient with an EML4-ALK gene rearrangement (a known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, ALK G1269A was reported to be refractory to cr… (full text at CIViC)

PMID 27045755 · Saber et al., 2016 · Open in CIViC

A 28 year-old patient with non-small cell lung cancer was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid i… (full text at CIViC)

PMID 20979473 · Choi et al., 2010 · Open in CIViC

In a stage IV Hodgkin's lymphoma patient with metastatic lung adenocarcinoma harboring an EML4-ALK gene rearrangement (a known sensitizing alteration to crizotinib) and an ALK L1196M�co-mutation, ALK … (full text at CIViC)

PMID 27507192 · Zhang et al., 2017 · Open in CIViC